Quantel Medical announced that it has received approval from the FDA for the Easyret fully integrated 577nm yellow photocoagulator, which is used to treat certain forms of macular edema and peripheral retinal pathologies.
The Easyret has a broad range of settings for treatment of pathologies such as diabetic retinopathy, macular edema, and central serous chorioretinopathy. In addition to SingleSpot treatment mode, surgeons can select "Multispot" mode for a pattern of simultaneous targets or the "SubLiminal" mode, which enables them to customize a train of short pulses to precisely manage the thermal effect on targeted tissues.
"This technical breakthrough is based on Quantel’s proprietary ELBA fiber laser technology, which the company has utilized in scientific and industrial areas. We are very excited to bring this technology to ophthalmic surgeons and their patients in the United States in 2017,” Jean?Marc Gendre, CEO of Quantel Medical, said in a company news release. “The Easyret’s ELBA fiber laser cavity delivers pure 577nm yellow wavelength in a uniform top-hat laser spot profile, making it ideal for ophthalmic applications. The technology is a compact, reliable variation on solid-state lasers that provides an extended lifetime of service. Quantel engineers worked closely with surgeons to design a fully integrated system with an intuitive interface to ensure optimal ergonomics and ease of use. Surgeons’ input was essential to the Easyret’s design, and we are pleased with their enthusiasm for this new technology.”